Compared with traditional de novo drug discovery, drug repurposing has become an
attractive drug discovery strategy due to its low-cost and high efficiency. Through a …

In the late 1960s, the medical need for new antibiotics began to be questioned, and the
pharmaceutical industry shifted its emphasis of antibacterials from that of a therapeutic …

Diclofenac sodium (Dc), an anti-inflammatory agent, has remarkable inhibitory action both
against drug-sensitive and drug-resistant clinical isolates of various Gram-positive and Gram …

Diclofenac sodium (Dc) was found to possess antibacterial activity against both drug-
sensitive and drug-resistant clinical isolates of Staphylococcus aureus, Listeria …

E. coli is the main agent of uncomplicated urinary tract infections (UTIs) and accounts for
more than 85% of recurrent cystitis and at least 35% of recurrent pyelonephritis. Despite the …

The evolution of support for the discovery and development of antibacterial (or antibiotic)
agents from the larger pharmaceutical companies to the entrepreneur-like small …

The appearance of multiresistant bacterial strains coupled with the globally ongoing
problem of infectious diseases point to the imperative need for novel and affordable …

Extensive use of antibiotics for urinary tract infections has led to the emergence of drug-
resistant microorganisms and one solution to this problem is to search for non-antibiotic …

Non-steroidal anti-inflammatory drugs are widely used to relieve pain, reduce inflammation,
high temperature and fever, and prevent blood clots. There are very few studies where some …

Investigations were carried out to determine in vitro antibacterial activity of commercial
antibiotics commonly used for the treatment of UTI patient and some herb extracts to clinical …